Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Glibenclamide

Classification: A

Drug products: Daonil®, Glibenklamid Recip

ATC code: A10BB01

Substances: glibenclamide

Summary

Controlled studies on difference between men and women in effect of glicenclamide are lacking, except for hyperglycemia in combination with stroke.

While some studies indicate that women have a higher risk of hypoglycemia during antidiabetic treatment than men, other smaller studies have not found any differences between men and women in the risk of hypoglecemia during glibenclamide treatment.
 
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of glibenclamide have been found.

Effects

A study investigated whether the use of glibenclamide both at the time of stroke and during hospitalization result in better neurological and functional outcomes in patients with diabetes mellitus. Improvements occurred in patients with nonlacunar strokes and were independent of sex [3].

Adverse effects

The ACCORD study (Action to Control Cardiovascular Risk in Diabetes) was a randomized, controlled trial designed to test the effect of intensive glucose control compared with standard control on cardiovascular outcomes in patients with type 2 diabetes. The study showed that women had a higher risk of hypoglycemia than men regardless of treatment [1].In a study of 57 reported cases of glibenclamide-associated hypoglycemia to the Swedish Adverse Drug Reactions Advisory Committee in 1983, there was a female preponderance (61%). However, no adjustments for proportion women and men prescribed glibenclamide were made, which makes the results difficult to interpret. Sex did not predict the clinical course of the hypoglycemic events [4]. A small retrospective case-control study of prolonged hypoglycemia in patients (5 men, 2 women) with end-stage renal disease and type 2 diabetes receiving glibenclamide found no association between risk of hypoglycemia and sex [5].

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Other information

An observational retrospective study compared the effects of glimepiride or glibenclamide treatment on body weight over 12 months of treatment in patients with type 2 diabetes. Sex had no significant influence on change in body weight or BMI [2].

Updated: 2019-02-26

Date of litterature search: 2014-06-03

References

  1. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340:b5444. PubMed
  2. Martin S, Kolb H, Beuth J, van Leendert R, Schneider B, Scherbaum WA. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Diabetologia. 2003;46:1611-7. PubMed
  3. Kunte H, Schmidt S, Eliasziw M, del Zoppo GJ, Simard JM, Masuhr F et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke. 2007;38:2526-30. PubMed
  4. Asplund K, Wiholm BE, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia. 1983;24:412-7. PubMed
  5. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000 Mar;35(3):500-5 PubMed
  6. Socialstyrelsens statistikdatabas . Stockholm: Socialstyrelsen. 2015 [cited 2016-03-14.] Socialstyrelsens statistikdatabas
  7. Läkemedelsverket. Läkemedelsboken 2014. Uppsala: Läkemedelsverket; 2014.

Authors: Linnéa Karlsson Lind, Desirée Loikas

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson